Thiel, Parker said to fund secretive T-cell biotech startup

Little is known about the stealthy I-O biotech.

A report from CNBC says that PayPal founder Peter Thiel and Facebook investor Sean Parker are investing in a new, secretive oncology biotech company.

The news service, quoting a “person familiar with the company's financing,” says the so-called 3T Biosciences has raised more than $12 million, with the seed investment being led by Thiel, reportedly once up for the FDA chief role and a serial biotech investor, and Parker, who recently injected $250 million into the immuno-oncology research field in an effort to boost cancer survival rates.

RELATED: Facebook, Napster pioneer Sean Parker sets up $250M immuno-oncology center


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

CNBC, quoting the anonymous source, says the stealthy startup is currently led by a “cancer biology Ph.D. student and investor, Asset Management Ventures’ principal Luke Lee, as well as a group of academics from Christopher Garcia's biology lab at Stanford.”

It’s said to be in the T-cell therapy space, and would add to a growing trend in this form of immuno-oncology upstarts.

It’s not unusual for early-stage biotechs to stay under the radar in their first 12-18 months as they build up seed investment and get through preclinical work.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.